Veracyte (VCYT) Q3 2026 Earnings Call Transcript

Veracyte reported Q3 2026 revenue of $151.8 million, up 15% year over year, and adjusted EBITDA of $41.2 million, or 27.2% of revenue; Decipher Prostate volume growth was 12%, about 1,000 tests below management's expectations. The company narrowed 2026 revenue guidance to $590 million–$593 million and cut testing revenue guidance to $571 million–$573 million, citing the Decipher shortfall. Management expects 10% volume growth but mid-single-digit revenue growth and a 22% adjusted EBITDA margin in 2027, while authorizing a $100 million share repurchase and completing the $150 million cash acquisition of Convergent Genomics.

Analysis

The key change is not a collapse in demand but a lower, less certain growth slope for Decipher after guideline-driven adoption pulled demand forward. That matters because the 2027 commercial build is being funded before the evidence catalysts and new products can reliably convert into revenue. The near-term risk is execution leverage: added field expense meets slower core growth, while newer bladder and breast offerings initially dilute revenue per test and require reimbursement work. UroAmp is strategically complementary, but its stated launch timing makes it a 2028+ option rather than a 2027 earnings offset. Afirma’s workflow improvement is a real operational benefit, but its year-over-year contribution fades as comparisons roll forward; prior-period collections also make reported growth a noisy measure of underlying demand.

Contrarian read: the volume guide does not itself establish share loss. Management cited new and reactivated physicians and stable ordering among established users; the more immediate issue may be low-risk utilization and sales-force distraction. Cash generation and the repurchase authorization provide downside support, but do not resolve the growth/margin trade-off. Without valuation and current price data, we cannot determine whether the reset is fully priced. Over 1–3 months, focus on Decipher orders and operating expense discipline; over 6–18 months, clinical evidence, guideline changes, payer coverage, and Prosigna case-mix determine whether growth reaccelerates. Thesis weakens if Decipher volume growth falls below management’s stated floor, or if margins fail to recover toward the exit-year target.

Key Decisions for Investors

• Keep VCYT at market weight or underweight pending a cleaner read on Decipher demand; avoid treating the repurchase authorization as a substitute for evidence of durable growth. No price-based entry is warranted without current valuation and trading data.
• Use the next one to two reports as the trigger: monitor Decipher volume versus the 12,000-test annual incremental floor, active/re-activated ordering physicians, and sales-and-marketing growth. A miss on volume or continued expense growth without improving utilization would support a more defensive stance.
• Do not capitalize UroAmp as a near-term earnings catalyst. Track publication/reimbursement milestones and the first commercial launch timing; delay or weak payer progress would push out the portfolio diversification thesis.
• Treat Prosigna adoption as an alert, not yet a growth underwriting assumption: verify repeat-order institutions, broader patient mix, realized ASP, and payer coverage beyond current Medicare eligibility before assigning meaningful revenue leverage.
• Falsification for the cautious view would be Decipher growth holding at or above management’s floor alongside improving physician utilization, plus margins tracking toward 25% exiting 2027; that combination would justify reassessing the underweight.